Skip to content
BHP

CagriSema (cagrilintide + semaglutide)

Cagrilintide + Semaglutide · NN9838 combination

Reviewed by the BestHealingPeptides Editorial Team ·

On this page

A Novo Nordisk fixed-dose combination of semaglutide (the licensed GLP-1 receptor agonist) with cagrilintide (a long-acting amylin analogue) — pairing two appetite-suppressing mechanisms in a single weekly subcutaneous injection. Novo Nordisk submitted a New Drug Application to the US FDA on 18 December 2025 for weight management, and the pivotal REDEFINE 1 and 2 trials were published in NEJM in 2025. In REDEFINE 4, an open-label comparison with tirzepatide 15 mg, Novo Nordisk reported that CagriSema did not meet the primary endpoint of non-inferiority. Not approved in the UK, EU or US as of 29 October 2026.

Mechanism of action

CagriSema pairs two mechanistically distinct appetite-suppressing peptides in a single weekly injection: cagrilintide (a long-acting amylin analogue engaging the calcitonin-receptor family and specifically the amylin receptor complex CTR + RAMP) and semaglutide (the licensed GLP-1 receptor agonist). The pharmacological rationale is complementary rather than redundant — amylin and GLP-1 act through distinct receptor systems in overlapping but non-identical central nervous system circuits regulating appetite and satiety.

Cagrilintide's amylin-mimetic mechanism engages hypothalamic and brainstem calcitonin-family receptors, driving satiety through pathways separate from GLP-1R engagement. Native amylin is co-secreted with insulin from pancreatic β-cells; its physiological role in postprandial satiety complements GLP-1's incretin-effect insulin secretion. The rationale for combining pharmacological amylin and GLP-1 receptor engagement is that the pathways are distinct, so each could contribute independently to reduced caloric intake.

Semaglutide's GLP-1R agonism has been discussed extensively elsewhere on this reference: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, central appetite reduction through hypothalamic and brainstem GLP-1R populations. In CagriSema, semaglutide provides the incretin arm; cagrilintide provides the amylin-receptor arm.

A Phase II trial in adults with type 2 diabetes (BMI 27 or higher, on metformin with or without an SGLT2 inhibitor; Frías et al., Lancet 2023; 92 participants) compared cagrilintide 2.4 mg + semaglutide 2.4 mg with each component alone over 32 weeks. Mean weight change was −15.6% with CagriSema, −5.1% with semaglutide alone and −8.1% with cagrilintide alone. In the Phase III REDEFINE 1 trial (adults with obesity without diabetes; Garvey et al., NEJM 2025; 3,417 participants), mean weight change at 68 weeks was −20.4% with CagriSema versus −3.0% with placebo.

This reference found no regulatory approval of cagrilintide as a standalone medicine.

In REDEFINE 1 (Garvey et al., NEJM 2025; 3,417 adults without diabetes), CagriSema produced mean weight change of −20.4% versus −3.0% with placebo over 68 weeks. In the open-label REDEFINE 4 head-to-head trial, Novo Nordisk reported that CagriSema (20.2%) did not meet the primary endpoint of non-inferiority to tirzepatide 15 mg (23.6%) by the treatment-regimen estimand. Novo Nordisk submitted CagriSema to the US FDA on 18 December 2025; it is not approved anywhere as of 29 October 2026.

— Notable finding

Research history

CagriSema is a fixed-dose combination of the long-acting amylin analogue cagrilintide 2.4 mg and the GLP-1 receptor agonist semaglutide 2.4 mg, developed by Novo Nordisk. The combination hypothesis — that amylin and GLP-1 agonism would produce additive weight loss through complementary appetite-regulatory mechanisms — was tested in a Phase 1b trial of cagrilintide with semaglutide 2.4 mg (Enebo et al., Lancet 2021) and a Phase II trial in type 2 diabetes (Frías et al., Lancet 2023).

The Phase III REDEFINE programme includes REDEFINE 1 (obesity without diabetes) and REDEFINE 2 (obesity with type 2 diabetes), both published in NEJM in 2025; REDEFINE 3, a cardiovascular outcomes trial that ClinicalTrials.gov lists as active, not recruiting with primary completion in 2027; and REDEFINE 4, a head-to-head trial against tirzepatide 15 mg. On 23 February 2026 Novo Nordisk announced that in REDEFINE 4 (84 weeks, 809 participants, open-label) CagriSema did not meet the primary endpoint of non-inferiority: weight loss was 20.2% with CagriSema versus 23.6% with tirzepatide by the treatment-regimen estimand, and 23.0% versus 25.5% if all participants adhered to treatment (company-reported).

Novo Nordisk announced on 18 December 2025 that it had submitted a New Drug Application to the US FDA for weight management, based on REDEFINE 1 and 2, and on 23 February 2026 said an FDA decision was anticipated by late 2026. As of 29 October 2026 CagriSema does not appear on the FDA's 2026 novel drug approvals list and is not approved in any jurisdiction. This reference found no announced UK or EU submission.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Reported CagriSema (cagrilintide + semaglutide) research-model dose ranges
ModelRouteReported rangeNote
Phase II type 2 diabetes (Frías 2023)Subcutaneous injectionCagrilintide 2.4 mg + semaglutide 2.4 mg weeklyBoth components escalated to 2.4 mg in the 32-week trial.
Phase III REDEFINE 1, 2 and 4 and the US FDA submissionSubcutaneous injectionCagrilintide 2.4 mg + semaglutide 2.4 mg once weeklyDose described in Novo Nordisk's 18 December 2025 announcement of the FDA submission. The titration schedule is not given in the sources used for this reference.
Not for research-chemical useNot applicableNot applicableCombination product not appropriate for research-chemical-community assembly.
Ranges reported in pre-clinical literature. For laboratory and research use only.

Reconstitution & storage

Summarised studies

Summarised research studies
YearModelOutcomeCitationSource
2023Adults with type 2 diabetes and BMI 27 or higher, Phase II RCTWeight change −15.6% (CagriSema) versus −5.1% (semaglutide) and −8.1% (cagrilintide) at 32 weeksFrías JP, Deenadayalan S, Erichsen L, et al. Lancet. 2023;402(10403):720-730PMID 37364590
2021Adults with overweight (otherwise healthy), Phase 1b RCTHalf-life 159-195 h (cagrilintide) and 145-165 h (semaglutide); no effect of cagrilintide on semaglutide exposureEnebo LB, Berthelsen KK, Kankam M, et al. Lancet. 2021;397(10286):1736-1748PMID 33894838
2025Adults with overweight or obesity without diabetes, Phase III RCT−20.4% (CagriSema) versus −3.0% (placebo) mean weight change at 68 weeksGarvey WT, et al. N Engl J Med. 2025 (REDEFINE 1; NCT05567796)PMID 40544433
2025Adults with overweight or obesity and type 2 diabetes, Phase III RCT−13.7% (CagriSema) versus −3.4% (placebo) mean weight change at 68 weeksDavies MJ, et al. N Engl J Med. 2025 (REDEFINE 2; NCT05394519)PMID 40544432
2026Adults with obesity, open-label Phase III RCTCompany-reported: non-inferiority to tirzepatide 15 mg not shown (20.2% vs 23.6%)Novo Nordisk company announcement, 23 February 2026 (NCT06131437); not located in a journal—

Cagrilintide-semaglutide 2.4 mg once weekly in adults with type 2 diabetes (Phase 2 trial)

Frías JP, Deenadayalan S, Erichsen L, et al. Lancet. 2023;402(10403):720-730 · 2023 · PMID 37364590

Phase II 32-week trial in 92 adults with type 2 diabetes and BMI 27 or higher on metformin with or without an SGLT2 inhibitor, comparing cagrilintide + semaglutide (CagriSema) with semaglutide alone and cagrilintide alone, all escalated to 2.4 mg. Mean weight change was −15.6% with CagriSema, −5.1% with semaglutide and −8.1% with cagrilintide; HbA1c changed by −2.2, −1.8 and −0.9 percentage points. CagriSema was superior to cagrilintide for HbA1c but not significantly different from semaglutide.

PubMed

Cagrilintide alone and in combination with semaglutide in overweight adults (Phase 1b trial)

Enebo LB, Berthelsen KK, Kankam M, et al. Lancet. 2021;397(10286):1736-1748 · 2021 · PMID 33894838

Randomised, placebo-controlled, multiple-ascending-dose Phase 1b trial in otherwise healthy adults aged 18-55 with BMI 27.0-39.9 (96 randomised, 95 exposed) of cagrilintide 0.16-4.5 mg added to semaglutide 2.4 mg. Most adverse events were mild to moderate. Half-life was 159-195 hours for cagrilintide and 145-165 hours for semaglutide 2.4 mg, and cagrilintide did not affect semaglutide exposure or elimination.

PubMed

Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1)

Garvey WT, et al. N Engl J Med. 2025 (REDEFINE 1; NCT05567796) · 2025 · PMID 40544433

Phase 3a, 68-week, double-blind trial in 3,417 adults without diabetes randomised to cagrilintide 2.4 mg + semaglutide 2.4 mg, semaglutide alone, cagrilintide alone or placebo. By the treatment-policy estimand, mean weight change was −20.4% with CagriSema versus −3.0% with placebo (estimated difference −17.3 percentage points). Gastrointestinal adverse events affected 79.6% of the CagriSema group and 39.9% of the placebo group.

PubMed

Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2)

Davies MJ, et al. N Engl J Med. 2025 (REDEFINE 2; NCT05394519) · 2025 · PMID 40544432

Phase 3a, 68-week, double-blind trial in 1,206 adults with type 2 diabetes and BMI 27 or higher randomised 3:1 to CagriSema 2.4 mg/2.4 mg or placebo. By the treatment-policy estimand, mean weight change was −13.7% versus −3.4%; 73.5% of the CagriSema group reached HbA1c of 6.5% or less versus 15.9% with placebo.

PubMed

CagriSema versus tirzepatide 15 mg in adults with obesity (REDEFINE 4)

Novo Nordisk company announcement, 23 February 2026 (NCT06131437); not located in a journal · 2026

Open-label 84-week trial in 809 randomised adults with obesity and one or more comorbidities comparing CagriSema 2.4 mg/2.4 mg with tirzepatide 15 mg. Novo Nordisk reported weight loss of 20.2% with CagriSema versus 23.6% with tirzepatide by the treatment-regimen estimand (23.0% versus 25.5% if all adhered to treatment) and that the trial did not meet its primary endpoint of non-inferiority. These are company-reported figures.

Safety profile

CagriSema is not approved, so there is no UK Summary of Product Characteristics; the figures below come from published trials and company announcements. In REDEFINE 1 (Garvey et al., NEJM 2025), gastrointestinal adverse events affected 79.6% of participants on CagriSema and 39.9% on placebo, mainly transient and mild to moderate. Novo Nordisk reported that these included nausea (55% vs 12.6%), constipation (30.7% vs 11.6%) and vomiting (26.1% vs 4.1%), and that discontinuations due to adverse events were 5.9% with CagriSema versus 3.5% with placebo in REDEFINE 1, and 8.4% versus 3% in REDEFINE 2 (Novo Nordisk, 18 December 2025).

In REDEFINE 2 (adults with type 2 diabetes; Davies et al., NEJM 2025), gastrointestinal adverse events were reported by 72.5% on CagriSema and 34.4% on placebo. In the Phase II trial in type 2 diabetes (Frías et al., Lancet 2023), adverse events were reported by 68% of the CagriSema group, 71% of the semaglutide group and 80% of the cagrilintide group; no level 2 or 3 hypoglycaemia and no fatal adverse events were reported.

The cardiovascular outcomes trial REDEFINE 3 (NCT05669755) is listed on ClinicalTrials.gov as active, not recruiting, with primary completion in 2027. This reference does not state a class warning for CagriSema because none has been issued in an approved label.

Reported contraindications & cautions

  • Not a licensed medicine — there is no UK Summary of Product Characteristics and no formal contraindication list
  • Semaglutide, one component, is licensed separately and has its own UK product information; see the semaglutide entry

Known formulation interactions

  • No approved product information exists for the combination, so no interaction list can be cited. See the semaglutide entry for the licensed component.

UK regulatory status

CagriSema is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any jurisdiction as of 29 October 2026. Novo Nordisk submitted a New Drug Application to the US FDA on 18 December 2025 and said an FDA decision was anticipated by late 2026; the FDA's 2026 novel drug approvals list (current to 20 October 2026) does not include it. This reference found no announced MHRA or EMA submission and makes no prediction about UK availability.

Without a marketing authorisation, CagriSema is not available as a medicine through MHRA-regulated UK channels. Semaglutide is licensed on its own, but the combination with cagrilintide is not. Supply for human use outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012.

CagriSema and its components are not named on the WADA Prohibited List; WADA's S0 category covers pharmacological substances not addressed elsewhere on the List that have no current government approval for human therapeutic use, so athletes should check its status with their anti-doping organisation. Not a controlled drug under the Misuse of Drugs Act 1971. For animal research under ASPA, both component peptides require standard project and personal licences.

Frequently asked questions

What is CagriSema?
CagriSema is a Novo Nordisk fixed-dose combination of two peptides, cagrilintide 2.4 mg (a long-acting amylin analogue) and semaglutide 2.4 mg (a GLP-1 receptor agonist), given as a once-weekly subcutaneous injection. Novo Nordisk submitted it to the US FDA on 18 December 2025 for weight management; it is not approved in the UK, EU or US as of 29 October 2026.
How does the combination produce additive weight loss?
Amylin (via calcitonin-family receptors) and GLP-1 (via GLP-1R) engage distinct central nervous system appetite-regulatory circuits. The proposed rationale is that combining both could add to appetite suppression because the pathways are distinct. In the Phase II trial in adults with type 2 diabetes (Frías et al., Lancet 2023; 92 participants), weight change was −15.6% with CagriSema, −8.1% with cagrilintide alone and −5.1% with semaglutide alone at 32 weeks.
How does CagriSema compare with tirzepatide?
Both are next-generation weight-loss combinations extending beyond GLP-1 monoagonism. Tirzepatide is a dual GLP-1R/GIPR agonist in a single molecule; CagriSema is a fixed-dose combination of amylin-analogue + GLP-1R agonist. Tirzepatide is MHRA-licensed; CagriSema is not. They have been compared head to head in REDEFINE 4 (open-label, 84 weeks, 809 participants): Novo Nordisk reported weight loss of 20.2% with CagriSema versus 23.6% with tirzepatide 15 mg (treatment-regimen estimand) and that CagriSema did not meet the primary endpoint of non-inferiority. These are company-reported figures. In type 2 diabetes, Novo Nordisk reported on 21 September 2026 that in REIMAGINE 5 CagriSema 1.0 mg/1.0 mg was superior to tirzepatide 5 mg for weight loss at week 60 (12.4% versus 9.1%, efficacy estimand) and non-inferior for HbA1c reduction (1.71% versus 1.67%); tirzepatide 5 mg is not its highest dose, and these results are also company-reported.
Is CagriSema available in the UK?
No — CagriSema is not MHRA-licensed. Novo Nordisk has announced a US FDA submission (18 December 2025) but this reference found no announced UK or EU submission, and it does not predict when, or whether, CagriSema might be licensed in the UK.
What is cagrilintide?
Cagrilintide is a long-acting amylin analogue (PubChem molecular weight 4409; C194H312N54O59S2) given once weekly in the CagriSema combination. In the Phase 1b trial its half-life was 159-195 hours. In REDEFINE 1, cagrilintide 2.4 mg alone was one of the comparison arms alongside CagriSema, semaglutide 2.4 mg and placebo. This reference found no regulatory approval of cagrilintide as a standalone medicine.
What do the published REDEFINE 1 and 2 trials of CagriSema show?
REDEFINE 1 (obesity without diabetes; NEJM 2025) reported −20.4% weight change with CagriSema versus −3.0% with placebo over 68 weeks in 3,417 adults. REDEFINE 2 (obesity with type 2 diabetes; NEJM 2025) reported −13.7% versus −3.4% in 1,206 adults. The REDEFINE 4 comparison with tirzepatide has been announced by Novo Nordisk but not located in a journal. REDEFINE 3, a cardiovascular outcomes trial, is listed as active, not recruiting. Other Phase III trials, including REDEFINE 5 and REIMAGINE 1, 2 and 3 in type 2 diabetes, have also been published.
Is CagriSema prohibited in sport?
CagriSema and its components are not named on the WADA Prohibited List. WADA's S0 category covers pharmacological substances not addressed elsewhere on the List that have no current government approval for human therapeutic use, so athletes should check its status with their anti-doping organisation.

References

  1. Cagrilintide-semaglutide 2.4 mg once weekly in adults with type 2 diabetes (Phase 2 trial). Frías JP, Deenadayalan S, Erichsen L, et al. Lancet. 2023;402(10403):720-730 (2023). PMID 37364590
  2. Cagrilintide alone and in combination with semaglutide in overweight adults (Phase 1b trial). Enebo LB, Berthelsen KK, Kankam M, et al. Lancet. 2021;397(10286):1736-1748 (2021). PMID 33894838
  3. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). Garvey WT, et al. N Engl J Med. 2025 (REDEFINE 1; NCT05567796) (2025). PMID 40544433
  4. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2). Davies MJ, et al. N Engl J Med. 2025 (REDEFINE 2; NCT05394519) (2025). PMID 40544432
  5. CagriSema versus tirzepatide 15 mg in adults with obesity (REDEFINE 4). Novo Nordisk company announcement, 23 February 2026 (NCT06131437); not located in a journal (2026).
  6. Frías et al. 2023 — Phase II CagriSema in type 2 diabetes (PMID 37364590)
  7. Enebo et al. 2021 — Phase Ib foundational (PMID 33894838)
  8. Garvey et al. 2025 — REDEFINE 1, NEJM (PMID 40544433)
  9. Davies et al. 2025 — REDEFINE 2, NEJM (PMID 40544432)
  10. Novo Nordisk — FDA submission of CagriSema, 18 December 2025
  11. Novo Nordisk — REDEFINE 4 headline results, 23 February 2026
  12. Novo Nordisk — REIMAGINE 5 headline results, 21 September 2026
  13. PubChem — cagrilintide (CID 171397054)
  14. ClinicalTrials.gov — REDEFINE programme
  15. MHRA — UK medicines regulator

Where to source CagriSema (cagrilintide + semaglutide) for laboratory research

The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.

  • PeptideAuthority.co.uk

    UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.

  • PeptideBarn.co.uk

    Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.

Related peptides